{"id":11986,"date":"2025-04-18T11:58:47","date_gmt":"2025-04-18T09:58:47","guid":{"rendered":"https:\/\/valintermed.com\/?p=11986"},"modified":"2025-04-18T11:58:47","modified_gmt":"2025-04-18T09:58:47","slug":"zabolevanie-svyazannoe-s-antitelami-k-mielinovomu-oligodendrotsitarnomu-glikoproteinu","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/disease-associated-with-antibodies-to-myelin-oligodendroglycoprotein\/","title":{"rendered":"Myelin oligodendrocyte glycoprotein antibody-associated disease"},"content":{"rendered":"
<\/div>\n

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease is a relatively new and specific form of demyelinating disorder of the central nervous system. This disease is associated with the formation of antibodies against myelin oligodendrocyte glycoprotein, which is important for the normal functioning of the myelin sheaths of neurons in the central nervous system. Patients affected by this disorder may experience a wide range of neurological symptoms, including vision loss, movement disorders, paralysis, and other neurological manifestations. From a clinical point of view, MOG-associated disease can manifest as acute neuritis, transient episodes of myelitis, or even a syndrome similar to multiple sclerosis, making it an important topic of research and diagnosis.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n